Table 2. Biophysical characterization of the lipid based formulations.
| Particle size (nm) | |||||||
|---|---|---|---|---|---|---|---|
| 30th | 50th | 70th | |||||
| Formulations | percentile | Zeta potential (mV) | pDNA encapsulation (%) | ||||
| K1-25 μg pDNA (cir) | 166 ± 30 | 269 ± 72 | 442 ± 160 | −24 ± 7 | 26 ± 2 | ||
| K2-25 μg pDNA (cir) | 169 ± 45 | 281 ± 89 | 506 ± 191 | 28 ± 4 | 95 ± 9 | ||
| K3-25 μg pDNA (cir) | 136 ± 14 | 191 ± 32 | 300 ± 101 | 18 ± 7 | 97 ± 4 | ||
| K4-2.5 μg pDNA (cir)* | 103 ± 10 | 169 ± 26 | 279 ± 54 | 12 ± 3 | ND* | ||
| K4-10 μg pDNA (cir) | 111 ± 27 | 168 ± 37 | 261 ± 66 | 13 ± 6 | ND | ||
| K4-25 μg pDNA (cir) | 126 ± 28 | 169 ± 39 | 262 ± 57 | 26 ± 4 | 98 ± 4 | ||
| K4-50 μg pDNA (cir) | 289 ± 26 | 567 ± 61 | 1095 ± 178 | −55 ± 8 | ND | ||
| K4- Lin*-25 μg pDNA | 141 ± 38 | 210 ± 72 | 355 ± 168 | 28 ± 5 | 81 ± 3 | ||
*Circular pDNA (cir); Linear pDNA (Lin); Not determined (ND).